Steven A. Rosenberg MD, PhD, FAACR
AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology

Steven A. Rosenberg MD, PhD, FAACR

Chief, Surgery Branch
National Cancer Institute
Bethesda, Maryland

For his discovery and visionary development of the first cell transfer immunotherapies in both solid and blood-based cancers.

The AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology recognizes an active scientist whose outstanding and innovative research has had a major impact on the cancer field and has the potential to stimulate new directions in cancer immunology.

Rosenberg is being recognized for his seminal discoveries that led to the first effective cancer immunotherapy, interleukin-2 (IL-2), and the first adoptive cell transfer immunotherapies for both solid and blood cancers, including genetically modified T cells.

Rosenberg’s research established IL-2 as a growth factor for antitumor T cells in mice and humans, both in vitro and in vivo, and demonstrated that treating patients with metastatic melanoma with high doses of IL-2 could induce long-term tumor regression. These landmark discoveries led to IL-2 becoming the first cancer immunotherapy approved by the U.S. Food and Drug Administration (FDA), and it has been used to treat patients with metastatic renal cell carcinoma and metastatic melanoma since the 1990s. To read more, please visit the press release.

View Dr. Rosenberg’s Fellows of the AACR Academy page

View Past Recipients